- Home
- RCS vs SMTI Comparison
RCS vs SMTI Comparison
Compare RCS & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- SMTI
- Stock Information
- Founded
- RCS 1994
- SMTI 1982
- Country
- RCS United States
- SMTI United States
- Employees
- RCS N/A
- SMTI N/A
- Industry
- RCS Investment Managers
- SMTI Medical/Dental Instruments
- Sector
- RCS Finance
- SMTI Health Care
- Exchange
- RCS Nasdaq
- SMTI Nasdaq
- Market Cap
- RCS 296.3M
- SMTI 252.1M
- IPO Year
- RCS N/A
- SMTI N/A
- Fundamental
- Price
- RCS $7.09
- SMTI $29.84
- Analyst Decision
- RCS
- SMTI Strong Buy
- Analyst Count
- RCS 0
- SMTI 2
- Target Price
- RCS N/A
- SMTI $49.50
- AVG Volume (30 Days)
- RCS 141.1K
- SMTI 51.0K
- Earning Date
- RCS 01-01-0001
- SMTI 08-11-2025
- Dividend Yield
- RCS 10.12%
- SMTI N/A
- EPS Growth
- RCS N/A
- SMTI N/A
- EPS
- RCS N/A
- SMTI N/A
- Revenue
- RCS N/A
- SMTI $91,569,883.00
- Revenue This Year
- RCS N/A
- SMTI $23.53
- Revenue Next Year
- RCS N/A
- SMTI $5.93
- P/E Ratio
- RCS N/A
- SMTI N/A
- Revenue Growth
- RCS N/A
- SMTI 34.65
- 52 Week Low
- RCS $4.51
- SMTI $25.86
- 52 Week High
- RCS $6.31
- SMTI $39.08
- Technical
- Relative Strength Index (RSI)
- RCS 68.31
- SMTI 53.37
- Support Level
- RCS $7.00
- SMTI $29.80
- Resistance Level
- RCS $7.16
- SMTI $30.94
- Average True Range (ATR)
- RCS 0.07
- SMTI 1.07
- MACD
- RCS -0.01
- SMTI 0.29
- Stochastic Oscillator
- RCS 80.26
- SMTI 73.17
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.